Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Praluent Deal Combines Price Break With Point-Of Sale Rebates; Express Scripts Wants To Do More

Executive Summary

Express Scripts expects to develop similar coverage agreements, including point-of-sale rebates, with other manufacturers. Upcoming migraine drugs may be candidates.

You may also be interested in...



Let's Make A Deal: Sanofi/Regeneron Extend A Hand On Praluent, Express Scripts Takes It

Express Scripts has agreed to give Praluent preferred access over Amgen's Repatha on its national formulary and is removing restrictions that have been a significant barrier to market access for the PCSK9 inhibitors.

UnitedHealthcare Will Apply About 80% Of Rebates At Point-Of-Sale

Insurer offers additional details on upcoming rebate program, including how it will protect contract confidentiality, and which members might use it the most.

New Migraine Drugs May Not Be Cost Effective In Patients With Other Options, ICER Suggests

Draft cost effectiveness report released by the Institute for Clinical and Economic Review uses $8,500 annual cost for Aimovig and fremanezumab as a "placeholder" price.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS123016

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel